Concord Repatriation General Hospital
Australia
- Country
- Australia
- Ownership
- Private
- Established
- 1942-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
23
Active:1
Completed:5
Trial Phases
4 Phases
Phase 1:1
Phase 3:1
Phase 4:3
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (21 trials with phase data)• Click on a phase to view related trials
Not Applicable
16 (76.2%)Phase 4
3 (14.3%)Phase 1
1 (4.8%)Phase 3
1 (4.8%)HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation
Not Applicable
Recruiting
- Conditions
- Hepatocellular CarcinomaHCC
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Concord Repatriation General Hospital
- Target Recruit Count
- 476
- Registration Number
- NCT04455932
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺Concord Repatriation General Hospital, Concord, New South Wales, Australia
🇦🇺Gosford Hospital, Gosford, New South Wales, Australia
Effect of Warmed Humidified CO2 on Peritoneum During Laparotomy
Not Applicable
Completed
- Conditions
- Peritoneum; InjuryPeritoneal Inflammation
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Concord Repatriation General Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02975947
- Locations
- 🇦🇺
Concord Repatriation General Hospital, Sydney, New South Wales, Australia
News
World-First Clinical Trial: LIGŌ 3D Bioprinting Device Revolutionizes Wound Treatment Using Patient's Own Cells
Australian biotechnology company Inventia Life Science has launched the world's first clinical trial of LIGŌ, a 3D bioprinting device that delivers patients' own cells directly to wound sites without requiring skin grafts.